These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32406095)

  • 1. The role of CDK6 in cancer.
    Nebenfuehr S; Kollmann K; Sexl V
    Int J Cancer; 2020 Dec; 147(11):2988-2995. PubMed ID: 32406095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CDK4 and CDK6: From Discovery to Therapy.
    Sherr CJ; Beach D; Shapiro GI
    Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
    Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
    Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
    J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
    Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Target of CDK6 Signaling Pathway for Cancer Treatment.
    Basnet R; Amissah OB; Basnet BB; Huang R; Sun Y; de Dieu Habimana J; Li Z
    Curr Drug Targets; 2024; 25(11):724-739. PubMed ID: 39039674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
    De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
    Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
    Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
    Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Yang C; Li Z; Bhatt T; Dickler M; Giri D; Scaltriti M; Baselga J; Rosen N; Chandarlapaty S
    Oncogene; 2017 Apr; 36(16):2255-2264. PubMed ID: 27748766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
    Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
    Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
    Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
    Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
    Ismail A; Bandla S; Reveiller M; Toia L; Zhou Z; Gooding WE; Kalatskaya I; Stein L; D'Souza M; Litle VR; Peters JH; Pennathur A; Luketich JD; Godfrey TE
    Clin Cancer Res; 2011 Jul; 17(13):4513-22. PubMed ID: 21593195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
    Casimiro MC; Velasco-Velázquez M; Aguirre-Alvarado C; Pestell RG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):295-304. PubMed ID: 24387133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4-CDK6 inhibitors induce autophagy-mediated degradation of DNMT1 and facilitate the senescence antitumor response.
    Bourdeau V; Ferbeyre G
    Autophagy; 2016 Oct; 12(10):1965-1966. PubMed ID: 27532423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective degradation of CDK6 by a palbociclib based PROTAC.
    Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.